Dr. Freudenreich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Department of Psychiatry
Boston, MA 02114Phone+1 617-912-7800Fax+1 617-723-3919
Summary
- Dr. Oliver Freudenreich is an Associate Professor of Psychiatry at Harvard Medical School and a Psychiatrist at Massachusetts General Hospital (MGH). He serves as Co-Director of the MGH Schizophrenia Clinical and Research Program and directs the MGH Fellowship in Public and Community Psychiatry.
His academic interest is in the area of optimal psychopharmacological treatment for schizophrenia, including clozapine for refractory psychosis, the role of medical morbidity in schizophrenia, the integration of medicine and psychiatry, and treatment adherence. In addition to his clinical and clinical trial expertise in schizophrenia, Dr. Freudenreich provides psychiatric consultations for medically complex patients with serious mental illness or diagnostically difficult cases with psychosis. He is a deputy editor for the journal Psychosomatics. He has published extensively in his areas of interest and he wrote a handbook on psychotic disorders; a second edition was published in 2020. Dr. Freudenreich is an active teacher who lectures regularly at national meetings and at his home institution. At MGH, he was for many years the course director for the Department of Psychiatry’s monthly Morbidity and Mortality conference and Grand Rounds.
Education & Training
- Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Psychiatry, 1995 - 1999
- Ruprecht Karl University Faculty of MedicineClass of 1994
Certifications & Licensure
- MA State Medical License 1999 - 2025
- ME State Medical License 2020 - 2025
- American Board of Psychiatry and Neurology Psychiatry
- American Board of Psychiatry and Neurology Psychosomatic Medicine
Clinical Trials
- Risperidone Augmentation in Patients With Schizophrenia Start of enrollment: 2003 Feb 01
- Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Study Start of enrollment: 2006 Jan 01
- Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults Start of enrollment: 2011 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 97 citationsAttitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.Oliver Freudenreich, Corinne Cather, A. Eden Evins, David C. Henderson, Donald C. Goff
The Journal of Clinical Psychiatry. 2004-10-15 - 81 citationsStrategies for improving treatment adherence in schizophrenia and schizoaffective disorder.Donald C. Goff, Michele Hill, Oliver Freudenreich
The Journal of Clinical Psychiatry. 2010-12-23 - 34 citationsCatatonia in the medically ill: Etiology, diagnosis, and treatment. The Academy of Consultation-Liaison Psychiatry Evidence-Based Medicine Subcommittee Monograph.Lex Denysenko, Nicole Sica, Thomas M. Penders, Kemuel L. Philbrick, Audrey Walker
Annals of Clinical Psychiatry. 2018-05-01
Other
- Guidelines for prescribing clozapine in schizophreniaFreudenreich O, McEvoy J
http://www.uptodate.com/contents/guidelines-for-prescribing-clozapine-in-schizophrenia
UpToDate, Wolters Kluwer Health - 2012-07-26
Press Mentions
- Karuna’s Experimental Schizophrenia Drug Succeeds in Advanced StudyAugust 8th, 2022
- Classification of Schizoaffective Disorder: The History of a Vexing ConceptMay 6th, 2020
- Suicide in Schizophrenia Spectrum DisordersApril 6th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: